My HappyStock
Log in to track your learning progress.
US Companies
Find my preferred stocks →Compare companies across six criteria and explore businesses that fit your priorities.
Amgen Inc. (AMGN)
Average score 7.3 B
Preference —
Amgen Inc.; Wikimedia Commons; PD-textlogo; trademark restrictions may apply
Six company scores
Newer drugs and acquired rare-disease brands lift sales
Biologic pricing and scale support strong margins
Strong cash flow, but acquisition debt remains high
Patents, clinical expertise and complex biologic production
Obesity and rare-disease pipeline; biosimilar risks persist
About 19x forward earnings already reflects growth hopes
Editorial scores are for education, not audited financial metrics or investment advice.
Revenue by business
- Cardiovascular Medicines 10.47%
Repatha cholesterol-lowering therapy
- Bone Health Medicines 16.12%
Prolia, EVENITY and XGEVA therapies
- Inflammation and Respiratory 15.73%
ENBREL, Otezla and TEZSPIRE treatments
- Oncology and Hematology 19.67%
BLINCYTO, IMDELLTRA and other cancer/blood drugs
- Rare Disease Medicines 13.47%
TEPEZZA, KRYSTEXXA and UPLIZNA therapies
- Other Medicines 19.89%
Aranesp and other marketed medicines
- Other Revenues 4.65%
Non-product revenue from licensing and collaborations
Revenue by region
- United States 73.45%
- Rest of World 26.55%
Key metrics
| Revenue CAGR (5 years) | 8% |
|---|---|
| Operating income CAGR (5 years) | -0% |
| Net income CAGR (5 years) | 1% |
| Operating margin (5-year avg.) | 28% |
| ROE (5-year avg.) | 102% |
| ROA (5-year avg.) | 8% |
| Beta (5 years) | 0.42 |
| MDD (5 years) | -27% |
| Payout ratio (5-year avg.) | 77% |
| P/E | 27x |
| Forward P/E | 19x |
| PEG | 3.46 |